Product Description
Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
AI Product Description
*The following content is generated by AI and is for reference only.
Pimecrolimus is a potent, non-steroidal immunomodulatory agent belonging to the ascomycin class of macrolactams. Its chemical identity is defined by the molecular formula C38H57NO10 and the CAS registry number 163498-21-5. Structurally, it acts as a macrocyclic lactone that specifically inhibits T-cell activation and proliferation without causing skin atrophy, a common side effect associated with traditional corticosteroids.
The primary clinical application of Pimecrolimus is the topical treatment of moderate-to-severe atopic dermatitis (eczema) in patients who are two years of age or older, particularly those who have not responded adequately to conventional therapies or for whom such treatments are contraindicated. It is widely recognized for its safety profile in sensitive areas, including the face, neck, and eyelids, where long-term steroid use poses significant risks. The drug functions by binding intracellularly to the immunophilin FKBP-12. This complex then inhibits calcineurin, an enzyme critical for the dephosphorylation of nuclear factor of activated T-cells (NFAT). By blocking this pathway, Pimecrolimus prevents the transcription of cytokines such as interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, effectively reducing inflammation and itching associated with eczema flare-ups.
Unlike corticosteroids, Pimecrolimus does not suppress the immune system systemically when applied topically, nor does it induce skin thinning or telangiectasia. This makes it an ideal first-line therapy for intermittent management of mild-to-moderate disease and a maintenance strategy for preventing relapses. While generally well-tolerated, minor local reactions like transient burning or stinging may occur upon initial application. Due to its mechanism of action, it offers a sustainable solution for chronic inflammatory skin conditions, improving quality of life while minimizing adverse effects. Regulatory agencies worldwide, including the FDA and EMA, have approved its use, establishing it as a cornerstone in modern dermatological care for managing atopic dermatitis safely and effectively over extended periods.